Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Lung inflammatory injury and tissue repair (Jul 2023)
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
At last — linking ORMDL3 polymorphisms, decreased sphingolipid synthesis, and asthma susceptibility
Marsha Wills-Karp
Marsha Wills-Karp
Published January 13, 2020
Citation Information: J Clin Invest. 2020;130(2):604-607. https://doi.org/10.1172/JCI134333.
View: Text | PDF
Commentary

At last — linking ORMDL3 polymorphisms, decreased sphingolipid synthesis, and asthma susceptibility

  • Text
  • PDF
Abstract

Asthma is a common chronic respiratory disease that has a heritable component. Polymorphisms in the endoplasmic reticular protein orosomucoid-like protein 3 (ORMDL3), which regulates sphingolipid homeostasis, have been strongly linked with childhood-onset asthma. Despite extensive investigation, a link between ORMDL3 asthma–risk genotypes and altered sphingolipid synthesis has been lacking. In this issue of the JCI, Ono et al. establish a clear association between nonallergic childhood asthma, lower whole-blood sphingolipids, and asthma-risk 17q21 genotypes. These results demonstrate that genetic variants in ORMDL3 may confer a risk of developing childhood asthma through dysregulation of sphingolipid synthesis. As such, modulation of sphingolipids may represent a promising avenue of therapeutic development for childhood asthma.

Authors

Marsha Wills-Karp

×

Figure 1

Potential role of genetic variants in ORMDL3 and childhood-onset asthma.

Options: View larger image (or click on image) Download as PowerPoint
Potential role of genetic variants in ORMDL3 and childhood-onset asthma....
The first and rate-limiting step in de novo SPH synthesis begins with the condensation of serine and palmitoyl-CoA by SPT to produce 3-ketosphingosine, which is rapidly converted to sphinganine. Sphinganine is then further metabolized by distinct ceramide synthases to dihydroceramides, which can then generate ceramides via dihydroceramide desaturases (DES1). Dihydroceramides can get phosphorylated to sphinganine-1-phosphate or get transported out of the ER to form complex sphingomyelins or glycosphingolipids. To maintain physiologic concentrations of SPHs in the ER, the lysosome can salvage and recycle complex SPHs (sphingomyelins, glycosphingolipids) from plasma membranes. As a consequence of increased ORMDL3 expression, de novo synthesis of SPHs is reduced. Reductions in whole-blood SPH levels have been associated with several features of childhood asthma including increased ASM contractility, airway remodeling, and airway hyperreactivity. GSL, glycosphingolipids; SM, sphingomyelins.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts